3 Top Biotech Stocks to Buy in October [The Motley Fool]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: The Motley Fool
Adding these biotech stocks to growth portfolios this month could prove to be profit-friendly. If Regeneron Pharmaceuticals ( NASDAQ:REGN ) , Incyte Corporation ( NASDAQ:INCY ) , and AbbVie Inc. ( NYSE:ABBV ) aren't on your list of stocks to consider buying this month, you might want to add them. These three Motley Fool contributors think new approvals could help drive Regeneron Pharmaceuticals and Incyte higher and that AbbVie has become a top stock on sale. Are these stocks worth including in your portfolio? Read on to find out. This biopharma stock has big news coming Todd Campbell (Regeneron Pharmaceuticals): If it's been a while since you last considered owning Regeneron Pharmaceuticals in your portfolio, now could be a good time to revisit it . IMAGE SOURCE: GETTY IMAGES. The company is best known for its multibillion-dollar blockbuster vision drug, Eylea, but over the past few years, it's won a slate of FDA approvals that are diversi
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Regeneron (REGN) Reports Next Week: What You Should Expect [Yahoo! Finance]Yahoo! Finance
- UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study [Yahoo! Finance]Yahoo! Finance
- AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study [Reuters]Reuters
- REFILE-AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study [Yahoo! Finance]Yahoo! Finance
- Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies [Seeking Alpha]Seeking Alpha
REGN
Earnings
- 2/2/24 - Beat
REGN
Sec Filings
- 4/3/24 - Form 4
- 4/3/24 - Form 4
- 4/1/24 - Form 144
- REGN's page on the SEC website